bioAffinity Technologies, Inc. - Common Stock (BIAF)
0.7800
-0.0600 (-7.14%)
bioAffinity Technologies, Inc. is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for the early detection and treatment of cancer
The company leverages its proprietary technologies to create advanced cellular and molecular products aimed at improving patient outcomes, particularly in areas where traditional methods fall short. By harnessing the power of biological mechanisms, bioAffinity seeks to provide healthcare professionals with novel tools for identifying cancer at its earliest stages and tailoring personalized treatment plans for patients.
Shares of Mesoblast Limited (NASDAQMESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The S&P 500 also rose, gaining, 0.53% to 5,105.72.
BioAffinity Technologies shares are trading lower by 50.7% during Wednesday's session. The company announced a securities purchase agreement with institutional investors.
Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
Shares of Compugen Ltd. (NASDAQCGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.
Gainers Gaucho Group Holdings, Inc. (NASDAQVINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2 million and $0.7 million respectively.
